| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1653979 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 2. | ALA1653980 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 3. | ALA1654675 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 4. | ALA1654676 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 5. | ALA1654790 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced systemic disease symptoms at 100 mg/kg, po qd measured after 9 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 6. | ALA1654791 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 7. | ALA1654792 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 8. | ALA1654793 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 9. | ALA1654794 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through dermal scarification route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 10. | ALA1654795 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 11. | ALA1654796 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intravenous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 12. | ALA1654797 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 13. | ALA1654798 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through subcutaneous route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 14. | ALA1654799 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced satellite lesion formation on tails at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 15. | ALA1654800 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through intraperitoneal route in BALB/c mouse assessed as protection against virus-induced conjunctivitis in mouse eyes at 100 mg/kg, po qd measured after 6 days postinfection | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 16. | ALA1654801 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in lungs at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 17. | ALA1654802 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in lungs at 100 mg/kg, po qd measured after 5 days postinfection by RT-PCR analysis relative to control | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 18. | ALA1654803 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in blood at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 19. | ALA1654804 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in spleen at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature | |
| 20. | ALA1654805 | Functional | Antiviral activity against Vaccinia virus WR ATCC VR-1354 infected through percutaneous route in BALB/c mouse assessed as reduction of viral load in liver at 100 mg/kg, po qd measured after 3 days postinfection by RT-PCR analysis relative to control | Vaccinia virus WR | 1 | ALA1649270 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!